Clinicopathological and prognostic significance of programmed death ligant-1 expression in gastric cancer: a meta-analysis

Qiu, Zhebing; Du, Yinguo

doi:10.21037/jgo-20-568

Cited by 15 publications

(16 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A more recent meta-analysis including 15 studies and 3218 patients from China, South Korea, Japan, and Germany, showed that PD-L1 expression was associated with a decrease in the 3-and 5-year survival rates. 52 In the subgroup analyses of ethnicity, PD-L1 expression in Asian patients was also associated with a decrease in the 3- and 5-year survival rates. PD-L1 expression was associated with lymph node metastasis but not with tumor staging.…”

Section: Biomarkers For Immune Checkpoint Inhibition In Gastric Cancermentioning

confidence: 92%

Recent insights into the use of immune checkpoint inhibitors in gastric cancer

Figueiredo

2022

Porto Biomedical Journal

View full text Add to dashboard Cite

Gastric cancer (GC) is the fifth most incident and the fourth deadliest cancer worldwide. GC is a heterogeneous disease from the histological and molecular standpoints. This malignancy is mostly diagnosed at advanced stages of the disease, where the available therapeutic interventions are not effective. The emergence of immunotherapy has transformed the landscape of cancer treatment, including GC, and currently immune checkpoint inhibitors have been approved for the treatment of patients with recurrent/metastatic GC. This review summarizes the main clinical trials evaluating the use of immune checkpoint inhibitors in GC. It also highlights the potential of biomarkers for patient selection for GC immune checkpoint inhibition therapy, including programmed cell death ligand 1 expression and tumor mutational burden, and characteristics of the GC molecular classification, such as microsatellite instability status and Epstein-Barr virus infection, as predictors of response to blockade of the programmed cell death 1/programmed cell death ligand 1 axis.

show abstract

Section: Biomarkers For Immune Checkpoint Inhibition In Gastric Cancermentioning

confidence: 92%

Recent insights into the use of immune checkpoint inhibitors in gastric cancer

Figueiredo

2022

Porto Biomedical Journal

View full text Add to dashboard Cite

show abstract

“…Several meta-analyses of the PD-L1 expression predictive value in GC have shown that PD-L1 expression is associated with a poor survival rate [ 17 , 18 , 19 , 20 , 21 ].…”

Section: Immune Checkpoint Expression In Connection With Clinical Features and The Therapeutic Efficacy Of Their Inhibitionmentioning

confidence: 99%

“…For example, in a meta-analysis from Gu et al, an association of PD-L1 expression in GC with such clinical characteristics as the depth of tumor invasion ( p = 0.03), lymph node metastasis ( p = 0.03), venous invasion ( p = 0.0003), Epstein-Barr virus (EBV) infection ( p < 0.0001), microsatellite instability (MSI) ( p = 0.0001) was found [ 18 ]. In another meta-analysis, PD-L1 expression in GC was associated with lymph node metastasis (OR = 1.73, 95% CI = 1.18–2.54, p < 0.001) [ 17 ]. In the study of Zhang et al there was an association of PD-L1 expression with tumor size and lymph node metastasis [ 19 ].…”

Section: Immune Checkpoint Expression In Connection With Clinical Features and The Therapeutic Efficacy Of Their Inhibitionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis

et al. 2021

View full text Add to dashboard Cite

To increase the effectiveness of anticancer therapy based on immune checkpoint (IC) inhibition, some ICs are being investigated in addition to those used in clinic. We reviewed data on the relationship between PD-L1, B7-H3, B7-H4, IDO1, Galectin-3 and -9, CEACAM1, CD155, Siglec-15 and ADAM17 expression with cancer development in complex with the results of clinical trials on their inhibition. Increased expression of the most studied ICs—PD-L1, B7-H3, and B7-H4—is associated with poor survival; their inhibition is clinically significant. Expression of IDO1, CD155, and ADAM17 is also associated with poor survival, including gastric cancer (GC). The available data indicate that CD155 and ADAM17 are promising targets for immune therapy. However, the clinical trials of anti-IDO1 antibodies have been unsatisfactory. Expression of Galectin-3 and -9, CEACAM1 and Siglec-15 demonstrates a contradictory relationship with patient survival. The lack of satisfactory results of these IC inhibitor clinical trials additionally indicates the complex nature of their functioning. In conclusion, in many cases it is important to analyze the expression of other participants of the immune response besides target IC. The PD-L1, B7-H3, B7-H4, IDO1 and ADAM17 may be considered as candidates for prognosis markers for GC patient survival.

show abstract

“…Immunotherapy can restore anti-tumor immune response, which can control and clear tumor cells ( 11 ). Currently, multiple meta-analyses have shown that the expression of PD-L1 on tumor cells exhibits predictive value for prognosis in a variety of tumors, including gastric cancer ( 12 ), malignant pleural mesothelioma ( 13 ), bone and soft tissue sarcomas ( 14 ), colorectal cancer ( 15 , 16 ), glioblastoma ( 17 ), nasopharyngeal carcinoma ( 18 ), and small cell lung cancer ( 19 ).…”

Section: Introductionmentioning

confidence: 99%

Prognostic Function of Programmed Cell Death-Ligand 1 in Esophageal Squamous Cell Carcinoma Patients Without Preoperative Therapy: A Systematic Review and Meta-Analysis

Cui

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundStudies investigating the correlation between the expression of programmed cell death-ligand 1 (PD-L1) and prognosis in patients with esophageal squamous cell carcinoma (ESCC) not receiving preoperative therapy have increased significantly, but conclusions remain inconclusive. Therefore, this study aimed to determine the association between clinical outcomes and expression of PD-L1 in ESCC patients without preoperative therapy.MethodsWe conducted a comprehensive literature search using four databases up to May 2020. Quality assessment was carried out according to the Newcastle–Ottawa Quality Assessment Scale (NOS). Hazard ratios (HRs) were used to analyze the association between PD-L1 expression with prognosis. Furthermore, we evaluated the correlation between PD-L1 and clinicopathological characteristics using odds ratios (ORs) and 95% confidence intervals (CIs).ResultsTwenty studies (19 publications) comprising 3,677 patients were included in this meta-analysis. We found that the expression of PD-L1 was not related to overall survival (OS, HR: 1.16, 95% CI: 0.94–1.42, p = 0.16) or disease-free survival (DFS, HR: 0.85, 95% CI: 0.66–1.10, p = 0.21) in ESCC. Furthermore, although PD-L1 expression was not significantly associated with sex, degree of differentiation, TNM stage, T stage, lymph node status, smoking, or alcohol use, the merged OR demonstrated that the expression of PD-L1 was higher in older patients compared to younger patients (OR: 1.40, 95% CI: 1.07–1.83, p = 0.01). No obvious publication bias was observed.ConclusionsOur present study illustrated that PD-L1 expression was not related to poor prognosis of ESCC patients not receiving preoperative therapy, albeit the association only showed a tendency for statistical significance. Notably, PD−L1 expression showed a significant association with age. This meta-analysis had several limitations; therefore, our results need to be verified through further large-scale and prospective studies.

show abstract

Clinicopathological and prognostic significance of programmed death ligant-1 expression in gastric cancer: a meta-analysis

Cited by 15 publications

References 31 publications

Recent insights into the use of immune checkpoint inhibitors in gastric cancer

Recent insights into the use of immune checkpoint inhibitors in gastric cancer

Expression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis

Prognostic Function of Programmed Cell Death-Ligand 1 in Esophageal Squamous Cell Carcinoma Patients Without Preoperative Therapy: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About